Drug Trial Radar · NCT06649266
Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
14
Actual
Start
Aug 21, 2024
Primary completion
Sep 24, 2026
Study completion Aug 2027
Sponsor
- Lead sponsor
- Ribocure Pharmaceuticals ABIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. The main questions it aims to answer are: Does drug RBD106 reduce the HDV RNA levels? What medical problems may participants experience when taking drug RBD1016? Researchers will compare drug RBD1016 to a placebo to see if drug RBD1016 works to treat chronic hepatitis D. Participants will: Receive drug RBD1016 or a placebo several times throughout the trial. Visit the clinic once every 4-6 weeks for checkups and tests.
Conditions
- Chronic Hepatitis D
Interventions
RBD1016Drug
RBD1016, active drug.
PlaceboDrug
Placebo that is identical in appearance and volume to the doses of active IMP.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change (log10 value) vs. baseline in HDV RNA levels in plasma at end of trial (Week 60).Time frame: 60 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Medicinsk enhet för Infektionssjukdomar, Karolinska Universitetssjukhuset Huddinge
Stockholm, Sweden
Infektionskliniken, Danderyds sjukhus
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.